Related Experiment Videos
Juvenile idiopathic arthritis: classification, clinical presentation and current treatments
Gunther E Dannecker1, Pierre Quartier
1Department of Pediatric Rheumatology, Olgahospital, Klinikum Stuttgart, Stuttgart, Germany. g.dannecker@klinikum-stuttgart.de
Insights
Juvenile idiopathic arthritis (JIA) is a complex condition with varied symptoms, affecting children under 16. While treatments have improved, a cure remains elusive, focusing on joint function and development.
Area of Science:
- Pediatric Rheumatology
- Immunology
Background:
- Juvenile idiopathic arthritis (JIA) encompasses diverse arthritic conditions with onset before age 16.
- Etiology is unknown, involving genetic and environmental factors.
- Improved pharmacologic treatments, including biologics, have enhanced patient prognosis.
Purpose of the Study:
- To review JIA classification and clinical manifestations.
- To provide an overview of current pharmacotherapies for JIA subgroups.
Main Methods:
- Literature review on JIA classification.
- Summary of clinical presentations across JIA subgroups.
- Analysis of pharmacologic treatment options for JIA.
Main Results:
- JIA presents heterogeneously with distinct clinical signs and symptoms per subgroup.
- Pharmacologic advancements, particularly biologics, have improved JIA management.
- No current treatment offers a cure for JIA.
Conclusions:
- JIA treatment requires a multidisciplinary pediatric rheumatology team for optimal care.
- Therapeutic goals include preserving joint function and supporting normal childhood development.
- While a cure is not yet available, effective management strategies are crucial.
Background:
The term juvenile idiopathic arthritis (JIA) describes a clinically heterogeneous group of arthritides. The onset in all subgroups is before 16 years of age, but each group presents with different clinical signs and symptoms. The cause of the disease is unknown, but both genetic and environmental factors are believed to be involved. Management of the disease has greatly improved in recent years due to advances in pharmacologic treatment options (especially with new biologic agents) and the prognosis for patients is better than ever before. However, none of the available drugs has a curative potential. This review provides an overview on the classification and the clinical symptoms of the defined subgroups of JIA as well as pharmacotherapies for it.
Conclusions:
Treatment of children with JIA is challenging and complex. Since lengthy therapy might be necessary, a multidisciplinary pediatric rheumatology team is crucial for optimal treatment. Although a cure is unknown at this time, adequate treatment aims to preserve function of the joints as well as normal childhood development.
Related Concept Videos
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Inflammatory Bowel Disease IV: Clinical Manifestations
Asthma-II: Pathophysiology and Classification
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
The JAK-STAT Signaling Pathway
Rheumatic Heart Disease III: Medical Management
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests